Cargando…

Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis

SIMPLE SUMMARY: In this bi-institutional analysis including 421 patients, we report an overall high biochemical-recurrence free survival rate (58% after three years) after positron-emission tomography (PET)-based salvage radiotherapy (sRT). Additionally, the strong prognostic effect of prostate spec...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt Hegemann, Nina-Sophie, Rogowski, Paul, Eze, Chukwuka, Schäfer, Christian, Stief, Christian, Lang, Sebastian, Spohn, Simon, Steffens, Rieke, Li, Minglun, Gratzke, Christian, Schultze-Seemann, Wolfgang, Ilhan, Harun, Fendler, Wolfgang Peter, Bartenstein, Peter, Ganswindt, Ute, Buchner, Alexander, Grosu, Anca-Ligia, Belka, Claus, Meyer, Philipp Tobias, Kirste, Simon, Zamboglou, Constantinos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698293/
https://www.ncbi.nlm.nih.gov/pubmed/33207785
http://dx.doi.org/10.3390/cancers12113395
_version_ 1783615797209333760
author Schmidt Hegemann, Nina-Sophie
Rogowski, Paul
Eze, Chukwuka
Schäfer, Christian
Stief, Christian
Lang, Sebastian
Spohn, Simon
Steffens, Rieke
Li, Minglun
Gratzke, Christian
Schultze-Seemann, Wolfgang
Ilhan, Harun
Fendler, Wolfgang Peter
Bartenstein, Peter
Ganswindt, Ute
Buchner, Alexander
Grosu, Anca-Ligia
Belka, Claus
Meyer, Philipp Tobias
Kirste, Simon
Zamboglou, Constantinos
author_facet Schmidt Hegemann, Nina-Sophie
Rogowski, Paul
Eze, Chukwuka
Schäfer, Christian
Stief, Christian
Lang, Sebastian
Spohn, Simon
Steffens, Rieke
Li, Minglun
Gratzke, Christian
Schultze-Seemann, Wolfgang
Ilhan, Harun
Fendler, Wolfgang Peter
Bartenstein, Peter
Ganswindt, Ute
Buchner, Alexander
Grosu, Anca-Ligia
Belka, Claus
Meyer, Philipp Tobias
Kirste, Simon
Zamboglou, Constantinos
author_sort Schmidt Hegemann, Nina-Sophie
collection PubMed
description SIMPLE SUMMARY: In this bi-institutional analysis including 421 patients, we report an overall high biochemical-recurrence free survival rate (58% after three years) after positron-emission tomography (PET)-based salvage radiotherapy (sRT). Additionally, the strong prognostic effect of prostate specific antigen (PSA) level prior to sRT in this patient cohort was observed in multivariate regression analyses. Finally, patients who received staging with two different PET tracers for sRT guidance (cholin vs. prostate specific membrane antigen (PSMA) PET) were compared via propensity score matching and no significant differences in biochemical-recurrent free survival BRFS between the two tracers were observed. ABSTRACT: The purpose of this analysis was primarily to analyze biochemical-recurrence free survival (BRFS) after positron emission tomography (PET)-guided salvage radiotherapy (sRT) in a large cohort, and to further compare BRFS after PSMA vs. choline PET/ computer tomography (CT)-based sRT. This retrospective analysis is based on 421 patients referred for PSMA or choline PET/CT after radical prostatectomy due to biochemically recurrent or persistent disease. BRFS (PSA: 0.2 ng/mL) was defined as the study endpoint. Cox regression analyses were performed to assess the impact of different clinical parameters on BRFS. Additionally, propensity score matching was performed to adjust patient cohorts (PSMA vs. choline PET/CT-based sRT). The median follow-up time was 30 months. BRFS at three years after sRT was 58%. In the multivariate analysis, only PSA before PET imaging and PSA before sRT were significantly associated with BRFS (p < 0.05). After propensity score matching, 272 patients were further analyzed; there was no significant difference in three-year BRFS between patients with PSMA PET-based vs. choline PET-based sRT (55% vs. 63%, p = 0.197). The present analysis confirmed the overall high BRFS rates after PET-based sRT and the strong prognostic effect of PSA level prior to sRT. PSMA PET-based sRT did not have superior BRFS rates when compared with choline PET-based sRT.
format Online
Article
Text
id pubmed-7698293
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76982932020-11-29 Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis Schmidt Hegemann, Nina-Sophie Rogowski, Paul Eze, Chukwuka Schäfer, Christian Stief, Christian Lang, Sebastian Spohn, Simon Steffens, Rieke Li, Minglun Gratzke, Christian Schultze-Seemann, Wolfgang Ilhan, Harun Fendler, Wolfgang Peter Bartenstein, Peter Ganswindt, Ute Buchner, Alexander Grosu, Anca-Ligia Belka, Claus Meyer, Philipp Tobias Kirste, Simon Zamboglou, Constantinos Cancers (Basel) Article SIMPLE SUMMARY: In this bi-institutional analysis including 421 patients, we report an overall high biochemical-recurrence free survival rate (58% after three years) after positron-emission tomography (PET)-based salvage radiotherapy (sRT). Additionally, the strong prognostic effect of prostate specific antigen (PSA) level prior to sRT in this patient cohort was observed in multivariate regression analyses. Finally, patients who received staging with two different PET tracers for sRT guidance (cholin vs. prostate specific membrane antigen (PSMA) PET) were compared via propensity score matching and no significant differences in biochemical-recurrent free survival BRFS between the two tracers were observed. ABSTRACT: The purpose of this analysis was primarily to analyze biochemical-recurrence free survival (BRFS) after positron emission tomography (PET)-guided salvage radiotherapy (sRT) in a large cohort, and to further compare BRFS after PSMA vs. choline PET/ computer tomography (CT)-based sRT. This retrospective analysis is based on 421 patients referred for PSMA or choline PET/CT after radical prostatectomy due to biochemically recurrent or persistent disease. BRFS (PSA: 0.2 ng/mL) was defined as the study endpoint. Cox regression analyses were performed to assess the impact of different clinical parameters on BRFS. Additionally, propensity score matching was performed to adjust patient cohorts (PSMA vs. choline PET/CT-based sRT). The median follow-up time was 30 months. BRFS at three years after sRT was 58%. In the multivariate analysis, only PSA before PET imaging and PSA before sRT were significantly associated with BRFS (p < 0.05). After propensity score matching, 272 patients were further analyzed; there was no significant difference in three-year BRFS between patients with PSMA PET-based vs. choline PET-based sRT (55% vs. 63%, p = 0.197). The present analysis confirmed the overall high BRFS rates after PET-based sRT and the strong prognostic effect of PSA level prior to sRT. PSMA PET-based sRT did not have superior BRFS rates when compared with choline PET-based sRT. MDPI 2020-11-16 /pmc/articles/PMC7698293/ /pubmed/33207785 http://dx.doi.org/10.3390/cancers12113395 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Schmidt Hegemann, Nina-Sophie
Rogowski, Paul
Eze, Chukwuka
Schäfer, Christian
Stief, Christian
Lang, Sebastian
Spohn, Simon
Steffens, Rieke
Li, Minglun
Gratzke, Christian
Schultze-Seemann, Wolfgang
Ilhan, Harun
Fendler, Wolfgang Peter
Bartenstein, Peter
Ganswindt, Ute
Buchner, Alexander
Grosu, Anca-Ligia
Belka, Claus
Meyer, Philipp Tobias
Kirste, Simon
Zamboglou, Constantinos
Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis
title Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis
title_full Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis
title_fullStr Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis
title_full_unstemmed Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis
title_short Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis
title_sort outcome after 68ga-psma-11 versus choline pet-based salvage radiotherapy in patients with biochemical recurrence of prostate cancer: a matched-pair analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698293/
https://www.ncbi.nlm.nih.gov/pubmed/33207785
http://dx.doi.org/10.3390/cancers12113395
work_keys_str_mv AT schmidthegemannninasophie outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis
AT rogowskipaul outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis
AT ezechukwuka outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis
AT schaferchristian outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis
AT stiefchristian outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis
AT langsebastian outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis
AT spohnsimon outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis
AT steffensrieke outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis
AT liminglun outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis
AT gratzkechristian outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis
AT schultzeseemannwolfgang outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis
AT ilhanharun outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis
AT fendlerwolfgangpeter outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis
AT bartensteinpeter outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis
AT ganswindtute outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis
AT buchneralexander outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis
AT grosuancaligia outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis
AT belkaclaus outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis
AT meyerphilipptobias outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis
AT kirstesimon outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis
AT zamboglouconstantinos outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis